Romy Kandzia

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 4 EPO patents. Top assignees: Icon Genetics Gmbh, Kentucky Bioprocessing, Inc., University of Southampton. Active years: 2010-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Romy Kandzia. Retrieved from https://idiyas.com/inventor/romy-kandzia

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 6.5

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Halle/Saale, DE (2014)
Halle, DE (2010 - 2019)

Company Filing History:

Kentucky Bioprocessing, Inc.

patents

1 out of 252

University of Southampton

patents

where one patent can have more than one assignee

Years Active: 2010-2019

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10435704 - Method of co-expressing a glycoprotein and a single-subunit olicosaccharyltransferase in a plant (2019-10-08),

2. 10052370 - HER2/Neu cancer vaccine (2018-08-21),

3. 10035994 - Plant-based recombinant butyrylcholinesterase production methods (2018-07-31),

4. 9688970 - Plant-based recombinant butyrylcholinesterase production methods (2017-06-27),

5. 8883420 - Process of clean cloning (2014-11-11),

6. 7718848 - Safe production of a product of interest in hybrid seeds (2010-05-18),

Title: The Innovative Contributions of Romy Kandzia

Introduction

Romy Kandzia is a prominent inventor based in Halle, Germany, known for her significant contributions to the field of biotechnology. With a total of six patents to her name, she has made remarkable strides in the development of innovative methods for producing glycoproteins and cancer vaccines.

Latest Patents

Among her latest patents is a method of co-expressing a glycoprotein and a single-subunit oligosaccharyltransferase in a plant. This process involves expressing a nucleic acid sequence that encodes a polypeptide with an N-glycosylation site, alongside a heterologous single-subunit oligosaccharyltransferase. Additionally, she has developed a HER2/Neu cancer vaccine, which is a protein conjugate designed to generate an immune response against the HER2/neu protein. This innovative vaccine includes an immunogenic carrier that is covalently bonded to the protein antigen.

Career Highlights

Romy has worked with notable companies such as Icon Genetics GmbH and Kentucky Bioprocessing, Inc. Her work in these organizations has allowed her to apply her expertise in biotechnology and contribute to groundbreaking research and development.

Collaborations

Romy has collaborated with esteemed colleagues, including Frank Thieme and Stefan Werner, further enhancing her innovative projects and expanding her impact in the field.

Conclusion

Romy Kandzia's work exemplifies the spirit of innovation in biotechnology, with her patents paving the way for advancements in glycoprotein production and cancer treatment. Her contributions continue to inspire future research and development in these critical areas.

Profile summary based on public USPTO records.